Inefficacy of fresh frozen plasma in the treatment of L-asparaginase-induced coagulation factor deficiencies during ALL induction therapy

Haematologica. 1995 Sep-Oct;80(5):451-3.

Abstract

A prospective longitudinal study was conducted to determine whether single-donor fresh frozen plasma (FFP) substitution was able to influence L-asparaginase-associated hypoproteinemia. Within a 36-month period, 20 of 42 children with ALL received a total of 42 prophylactic FFP doses at a median of 10 (5-20) mliter/kg when fibrinogen levels decreased to < 60 mg/dL and thrombin time was lengthened. Laboratory monitoring before, during and after FFP substitution showed no short-term improvements and demonstrated only a minimal increase in fibrinogen and alpha 2-antiplasmin. Plasma levels of antithrombin and plasminogen remained unchanged. Furthermore, administration of FFP had no influence on thrombin generation, the plasmin/alpha 2-antiplasmin complex or enhanced D-dimer formation.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Afibrinogenemia / chemically induced
  • Antifibrinolytic Agents*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Antithrombins / deficiency
  • Asparaginase / administration & dosage
  • Asparaginase / adverse effects*
  • Blood Coagulation Disorders / chemically induced*
  • Blood Coagulation Disorders / therapy*
  • Fibrin Fibrinogen Degradation Products / analysis
  • Fibrinolysin / analysis
  • Plasma*
  • Plasminogen / deficiency
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Protein C / analysis
  • Thrombin Time
  • Treatment Failure
  • alpha-2-Antiplasmin / analysis

Substances

  • Antifibrinolytic Agents
  • Antithrombins
  • Fibrin Fibrinogen Degradation Products
  • Protein C
  • alpha-2-Antiplasmin
  • plasmin-plasmin inhibitor complex
  • Plasminogen
  • Fibrinolysin
  • Asparaginase